Indoco Remedies Limited
All news and filings related to Indoco Remedies Limited.
View all news & filings- Medium impact
Indoco Remedies' Goa Facility Cleared by UK MHRA with No Critical/Major Observations
Indoco Remedies' solid dosage manufacturing facility (Plant I) in Goa underwent a UK MHRA cGMP inspection from September 7-9, 2026. The inspection concluded with no critical or major observations. This facility is crucial for international business, contributing about 30% to total international sales.
Read the summary - Medium impact
Indoco Remedies' Goa Facility Receives 7 Observations from USFDA Inspection
Indoco Remedies' manufacturing facility in Goa was inspected by the USFDA from August 27 to September 4, 2026. The company received seven observations in Form 483. Indoco is addressing these observations and will respond to the USFDA within the stipulated timeframe.
Read the summary - Low impact
Indoco Remedies Sells Mumbai Land Parcel for ₹64 Crore
Indoco Remedies Limited sold a plot of land in Mumbai's Mahal Industrial Estate for ₹64 crore on August 27, 2026. The land measures 2,876.08 square meters. The sale is not expected to impact business operations and does not involve related parties.
Read the summary - Low impact
Indoco Remedies to Hold 79th AGM on Sep 17, 2026, for E-voting
Indoco Remedies Limited will hold its 79th AGM on September 17, 2026, via VC/OAVM. Remote e-voting is open from September 10 to September 16, 2026. The Annual Report for FY2025-26 was dispatched on August 21, 2026.
Read the summary - Low impact
Indoco Remedies Limited Files Business Responsibility and Sustainability Report for FY2025-26
Indoco Remedies Limited filed its BRSR for FY2025-26. The report details operations, ESG targets, and sustainability initiatives. Key achievements include a 43.5% renewable energy mix and an 18.6% reduction in Scope 1 emissions. The company aims for a 3% reduction in freshwater, energy, and GHG emissions by 2030.
Read the summary - Medium impact
Indoco Remedies Announces 79th AGM on Sep 17, 2026; Proposes Final Dividend of ₹0.20
Indoco Remedies will hold its 79th AGM on September 17, 2026. The company proposes a final dividend of ₹0.20 per share for FY26. Key events include e-voting from September 13-16, 2026. Ms. Aditi Panandikar's reappointment as MD and Dr. Vasudha Kamat's continuation as Independent Director are on the agenda. The company also seeks to increase borrowing limits to ₹1,500 Crores.
Read the summary - Low impact
Indoco Remedies Fixes Record Date for Final Dividend and AGM on September 10, 2026
Indoco Remedies Limited has set September 10, 2026, as the record date for its final dividend of ₹0.20 per equity share and for e-voting for the AGM. The book closure is from September 11 to September 17, 2026. The AGM is scheduled for September 17, 2026.
Read the summary - Low impact
Indoco Remedies Announces 79th AGM on Sep 17, 2026, with Dividend Recommendation
Indoco Remedies will hold its 79th AGM on September 17, 2026, via VC/OAVM. The company recommended a final dividend of ₹0.20 per equity share for FY2025-26, subject to shareholder approval. The Record Date is September 10, 2026, and Book Closure is from September 11-17, 2026.
Read the summary - Medium impact
Indoco Remedies Q1 FY27: Revenue Grows 8.2% to ₹4,662 Million; Baddi Unit III Gets EU-GMP
Indoco Remedies reported Q1 FY27 consolidated revenue of ₹4,662 million, up 8.2% YoY. Standalone revenue grew 5.8% to ₹4,081 million. EBITDA margin was 10.3% standalone. Key facilities received EU-GMP certification and cleared USFDA inspection. Domestic formulations revenue was ₹2,040 million, and API business surged 42% to ₹522 million.
Read the summary - High impact
Indoco Remedies Q1FY27 Unaudited Results: Standalone Profit ₹823 Crore, Consolidated ₹654 Crore
Indoco Remedies reported Q1FY27 unaudited standalone net profit of ₹82.32 crore, a significant increase from ₹27.36 crore in Q4FY26 and a loss in Q1FY26. Consolidated net profit was ₹65.44 crore, up from ₹23.68 crore in Q4FY26 and a loss in Q1FY26. Total income from operations was ₹408.97 crore (standalone) and ₹467.50 crore (consolidated).
Read the summary - Low impact
Indoco Remedies: Audio Recording of Q1 FY27 Earnings Call Available
Indoco Remedies released the audio recording of its Q1 FY27 earnings conference call held on July 28, 2026. The call covered unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The recording is available on the company's website.
Read the summary - Medium impact
Indoco Remedies Appoints Sudhir Kadam as Sr. VP (HR), Reappoints Aditi Panandikar as MD
Indoco Remedies re-appointed Ms. Aditi Panandikar as Managing Director for 5 years from Feb 15, 2027. Mr. Sudhir Kadam appointed Sr. VP (Human Capital) effective July 28, 2026. Both appointments are subject to necessary approvals.
Read the summary - Medium impact
Indoco Remedies Reappoints Aditi Panandikar as MD, Appoints Sudhir Kadam as Sr. VP
Indoco Remedies re-appointed Ms. Aditi Panandikar as Managing Director for 5 years from Feb 15, 2027, pending shareholder approval at the 79th AGM. Mr. Sudhir Kadam was appointed Sr. Vice President (Human Capital) effective July 28, 2026. Both appointments were approved by the Board on July 28, 2026.
Read the summary - Medium impact
Indoco Remedies Q1 FY27 Unaudited Results: Revenue Up 6% YoY to ₹408.1 Crore, EBITDA ₹42.2 Crore
Indoco Remedies reported Q1 FY27 unaudited results. Standalone revenue grew 6% YoY to ₹408.1 Crore. EBITDA improved significantly to ₹42.2 Crore from ₹14.8 Crore YoY. Consolidated revenue was ₹467.5 Crore. The company recognized an exceptional gain of ₹97.34 Crore from the sale of its Ophthalmic Business Division. Management highlighted steady progress in domestic and international businesses.
Read the summary - Low impact
Indoco Remedies schedules Q1 FY27 earnings call for July 28, 2026
Indoco Remedies Limited will hold an Earnings Conference Call on July 28, 2026, at 3:30 PM IST to discuss unaudited financial results for the quarter ended June 30, 2026. Key management will be present.
Read the summary - Low impact
Indoco Remedies: Trading Window Closed for Q1 FY27 Results
Indoco Remedies will close its trading window from July 1, 2026, until 48 hours after the declaration of Q1 FY27 unaudited financial results. Designated persons are prohibited from trading shares during this period.
Read the summary - Low impact
Indoco Remedies to Transfer Unclaimed Dividends and Shares to IEPF by Oct 3, 2026
Indoco Remedies will transfer unclaimed dividends and shares to the IEPF by October 3, 2026. Shareholders who have not claimed dividends for seven consecutive years must act before this deadline. This notice pertains to unclaimed dividends, including for FY 2018-19. Details are available on the company's website and through the RTA.
Read the summary - Medium impact
Indoco Remedies' Baddi Plant Receives EU GMP Certification Post-Inspection
Indoco Remedies' Baddi Plant III received EU GMP certification from the German Health Authority. The certification follows an inspection from April 22-27, 2026, confirming compliance with Good Manufacturing Practice requirements. This achievement underscores the company's commitment to quality for global patients.
Read the summary - Medium impact
Indoco Remedies Completes Transfer of Ophthalmic Business to Sunways India
Indoco Remedies Limited has completed the transfer of its Ophthalmic Division to Sunways (India) Private Limited on May 18, 2026. The business was transferred as a going concern on a slump sale basis across India and several African territories. This follows the approval and execution of the Agreement to Transfer Business.
Read the summary - Medium impact
Indoco Remedies Director Dr. Anand Nadkarni Passes Away
Indoco Remedies Limited regrets to inform about the sad demise of its Non-Executive Director, Dr. Anand Nadkarni, on May 15, 2026. His passing is considered an irreparable loss to the company.
Read the summary - Medium impact
Indoco Remedies Baddi Facility Receives EU GMP Certification from Malta Medicines Authority
Indoco Remedies' Baddi Unit I manufacturing facility has received EU GMP certification from the Malta Medicines Authority after an inspection from January 29 to February 3, 2026. Managing Director Aditi Panandikar stated this reflects the company's commitment to quality and global standards.
Read the summary - Medium impact
Indoco Remedies Releases Q4 FY26 Earnings Call Transcript
Indoco Remedies' Q4 FY26 earnings call transcript reveals a return to profitability driven by international business growth. Standalone revenue rose 25.8% to ₹429.1 crore, and consolidated revenue increased 18.8% to ₹455.9 crore. International formulations grew 94.6% to ₹214.7 crore. The company is hiving off its ophthalmic business to focus on core areas and plans no major CAPEX for two years.
Read the summary - Low impact
Indoco Remedies Publishes Audited Financial Results for Q4FY26 in Newspapers
Indoco Remedies Limited published its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The results were advertised in Business Standard and Mumbai Lakshadeep on May 8, 2026.
Read the summary - Low impact
Indoco Remedies: Audio recording of Q4 FY26 earnings call available on website
Indoco Remedies Limited has made the audio recording of its Q4 FY26 earnings conference call available on its website. The call, held on May 7, 2026, discussed the company's audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Read the summary - Medium impact
Indoco Remedies Recommends Dividend of ₹0.20/Share, Reports Audited FY26 Results
Indoco Remedies Limited's Board approved audited financial results for FY26. The company recommended a dividend of ₹0.20 per equity share for FY26, subject to shareholder approval. The Board Meeting took place on May 7, 2026.
Read the summary - Medium impact
Indoco Remedies Board Approves Audited FY26 Results & Recommends ₹0.20 Dividend
Indoco Remedies Limited's Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. They recommended a dividend of ₹0.20 per equity share for FY 2025-2026, pending shareholder approval at the AGM.
Read the summary - Medium impact
Indoco Remedies Sells Ophthalmic Division for ₹110 Crore
Indoco Remedies Limited will sell its Ophthalmic Division to Sunways (India) Private Limited for ₹110 Crores on a slump sale basis. The division contributed ₹47.79 Crores revenue in FY25. The transaction is expected to complete in three months and allows Indoco to focus on core areas.
Read the summary - Medium impact
Indoco Remedies Agrees to Transfer Ophthalmic Division to Sunways India
Indoco Remedies approved the transfer of its ophthalmic business in India and Africa to Sunways India. This strategic divestment allows Indoco to focus on core therapeutic areas with higher potential. Sunways aims to strengthen its ophthalmology platform with this acquisition.
Read the summary - Medium impact
Indoco Remedies to Sell Ophthalmic Business for ₹110 Crore to Sunways
Indoco Remedies will sell its Ophthalmic Division for ₹110 Crores to Sunways (India) Private Limited. The division contributed ₹47.79 Crores in revenue in FY25. The sale is part of a strategy to focus on core therapeutic areas and is expected to be completed in approximately three months.
Read the summary - Low impact
Indoco Remedies to hold earnings conference call on May 7, 2026, for Q4 FY26 results
Indoco Remedies will host an earnings conference call on Thursday, May 7, 2026, at 3:30 PM IST to discuss audited financial results for the quarter and year ended March 31, 2026. Key management will be present.
Read the summary - Medium impact
Indoco Remedies' Aurangabad Testing Facility Cleared by US FDA with Zero Observations
Indoco Remedies' testing facility in Aurangabad successfully completed a U.S. FDA Pre-Approval Inspection. The inspection, held from April 8-10, 2026, concluded with zero form 483 observations.
Read the summary - Low impact
Indoco Remedies: Compliance Certificate Under SEBI Regulations for Q4FY26
Indoco Remedies Limited received a compliance certificate for Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate covers the quarter ended March 31, 2026, and confirms the proper processing and listing of dematerialised securities by the Registrar and Transfer Agent, MUFG Intime India Private Limited.
Read the summary - Low impact
Indoco Remedies Re-appoints Cost and Internal Auditors for FY27
Indoco Remedies Limited's Board re-appointed M/s Joshi Apte and Associates as Cost Auditors and M/s. Suresh Surana & Associates LLP as Internal Auditors for FY2026-2027. The re-appointments were approved during a board meeting held on March 31, 2026.
Read the summary - Low impact
Indoco Remedies: Trading Window Closed from April 1, 2026, for Q4FY26 Results
Indoco Remedies' trading window will be closed from April 1, 2026, until 48 hours after the declaration of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Designated persons are restricted from trading equity shares during this period.
Read the summary - Low impact
Indoco Remedies to Participate in 11th Annual Valorem Conference on March 23, 2026
Indoco Remedies Limited will participate in the 11th Annual Valorem Conference. Senior management will attend a group meeting on March 23, 2026, at 09:00 am, held physically at Grand Hyatt, Santacruz. No unpublished price-sensitive information will be shared.
Read the summary - Medium impact
Indoco Remedies Receives Final USFDA ANDA Approval for Brivaracetam Oral Solution
Indoco Remedies received final USFDA ANDA approval for Brivaracetam Oral Solution, 10 mg/mL, a generic equivalent to UCB Inc.'s Briviact. Manufactured in Goa, it treats partial-onset seizures. Ms. Aditi Panandikar highlighted this as a key milestone for expanding presence in regulated markets.
Read the summary - Medium impact
Indoco Remedies Q3 FY26 Earnings Call Transcript Released
Indoco Remedies' Q3 FY26 earnings call transcript reveals consolidated net revenues of INR4,343 million, up 7.9% YoY. International formulations grew 26.2%, and API business rose 24%. The company launched new OTC products in India and aims for over 20% revenue growth in Europe in the coming years. Total debt is around INR900 crores.
Read the summary - Low impact
Indoco Remedies: GST Inspection Concluded by Maharashtra Dept.
Indoco Remedies Limited announced the conclusion of a GST inspection by the Maharashtra State GST Department on February 8, 2026. The company has provided all requested information and stated that there is no material impact on its financials or operations.
Read the summary - Low impact
Indoco Remedies Publishes Unaudited Q3 FY26 Financial Results in Newspapers
Indoco Remedies Limited published its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The results were advertised in Business Standard and Mumbai Lakshadeep on February 4, 2026.
Read the summary - Low impact
Indoco Remedies Q3 FY26 Earnings Conference Call Audio Recording Available
Indoco Remedies Limited has released the audio recording of its Q3 FY26 earnings conference call. The call, held on February 3, 2026, discussed unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The recording is available on the company's website.
Read the summary - Medium impact
Indoco Remedies Q3 FY26 Revenue Up 7% to ₹389.6 Crore, EBITDA Grows 29%
Indoco Remedies reported Q3 FY26 revenue of ₹389.6 crore, up 7% YoY. EBITDA grew 29% to ₹25.9 crore. The company cited strong performance in Export Formulations and API businesses. Standalone net loss was ₹20 crore, and consolidated net loss was ₹29.45 crore for the quarter.
Read the summary - Medium impact
Indoco Remedies Under GST Inspection at Registered Office
GST authorities visited Indoco Remedies' registered office on February 2nd, 2026, for inspection under CGST and SGST Acts. The proceedings are ongoing, and the company is cooperating. No specific allegations have been received yet, and the financial impact is not quantifiable.
Read the summary - Medium impact
Indoco Remedies Receives USFDA Final ANDA Approval for Lacosamide Oral Solution USP
Indoco Remedies received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Lacosamide Oral Solution USP, 10 mg/mL. This generic product is equivalent to UCB, Inc.'s Vimpat Oral Solution. The drug will be manufactured in India. Managing Director Aditi Panandikar highlighted the approval reinforces the company's commitment to global healthcare.
Read the summary - Low impact
Indoco Remedies Schedules Q3FY26 Earnings Conference Call for Feb 3, 2026
Indoco Remedies Limited will hold an earnings conference call on February 3, 2026, at 3:30 PM IST to discuss financial results for the quarter and nine months ended December 31, 2025. Key management personnel will attend the call.
Read the summary - Low impact
Indoco Remedies Files Compliance Certificate for Q3 FY26
Indoco Remedies Limited filed a compliance certificate for Q3 FY26 ended December 31, 2025. The Registrar and Transfer Agent confirmed processing of dematerialised securities and updates to the register of members within timelines. No rematerialisation requests were received.
Read the summary - Low impact
Indoco Remedies: Trading Window Closed for Q3 FY26 Results
Indoco Remedies' trading window will be closed from January 1, 2026, until 48 hours after the declaration of unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. Designated persons are restricted from trading.
Read the summary - Medium impact
Kare Family Trust Acquires 6% Stake in Indoco Remedies, Enhancing Promoter Holding
Kare Family Private Trust acquired 6.00% (55,34,874 shares) of Indoco Remedies directly from Aruna Suresh Kare. KFPT also indirectly acquired stakes through promoter companies SIPL and SHPL. This increases KFPT's direct shareholding to 14.20% and enhances overall promoter holding.
Read the summary - Low impact
Indoco Remedies to Meet Analysts/Investors at Dolat Capital Conference on Feb 18, 2026
Indoco Remedies Limited's senior management will attend the Dolat Capital Corporate Conference 2026 on February 18th, 2026. The physical group meeting will be held at Grand Hyatt, Santacruz, Mumbai. No price-sensitive information will be disclosed.
Read the summary - Medium impact
Indoco Remedies: Kare Family Trust to Acquire Shares from Promoter
Kare Family Private Trust (KFPT) proposes to acquire shares of Indoco Remedies Limited. The acquisition includes 55,34,874 shares directly from Aruna Suresh Kare (6% stake) and indirect stakes via SIPL (40%) and SHPL (20.16%). The transaction is a family arrangement for succession planning and is set to occur on or after December 25th, 2025.
Read the summary - Medium impact
Indoco Remedies Receives Establishment Inspection Report from USFDA for Patalganga API Facility
Indoco Remedies has received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility in Patalganga. The facility was successfully inspected from September 15-19, 2025. This reinforces the company's commitment to quality and compliance.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio